CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RESPILIQ addresses hypercapnia, a condition affecting premature babies and patients with lung issues, by utilizing the human gut to excrete carbon dioxide. This innovative approach aims to improve patient outcomes and quality of life through oral or rectal administration.
Premature babies and patients with acute lung failure in the intensive care unit or COPD patients at home: they all suffer from the same potentially fatal condition: hypercapnia = an increased level of CO2 in the blood.
In Europe alone there are around 1.8M people.
Hypercapnia is one of the major challenges in the therapy of acute lung failure and long-term weaning in ICU and in the outpatient treatment of COPD, which has not yet been adequately solved.
Our goal is to revolutionize therapy and s…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 topics.
Guests see up to 5 keywords.
